Multiple Myeloma Hub What are the pros and cons of bispecific antibodies for multiple myeloma?
Jul 25, 2022
Experts Roberto Mina and Andrzej J. Jakubowiak discuss the pros and cons of bispecific antibodies for multiple myeloma, highlighting MajesTEC-1 and MagnetisMM-1 trials, efficacy, response rates, challenges like infection risks, comparison to CAR T-cell therapies, and sequencing of therapies in myeloma treatment.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Advancements in Bi-Specific Antibodies for Multiple Myeloma
01:49 • 12min
Comparing CAR-T and Bi-specific Antibodies in Multiple Myeloma Treatment
13:59 • 8min
Exploring the Use of Bispecific Antibodies in Multiple Myeloma Treatment
21:50 • 2min
Comparing CARTY Cells and Bi-specific Antibodies in Multiple Myeloma Treatment
23:59 • 4min